Wuhan Hiteck Biological Pharma Co.,Ltd (SHE:300683)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2020	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Jan 1, 2020	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Medical Technical Services Reporting Segment	257.25M	422.82M	390.70M	319.40M	281.29M
Medical Technical Services Reporting Segment Growth	-39.16%	8.22%	22.32%	13.55%	-
Biopharma	231.95M	161.05M	157.70M	158.65M	185.75M
Biopharma Growth	44.02%	2.12%	-0.59%	-14.59%	-
Production and Sales of Raw Materials and Pharmaceutical Intermediates	64.72M	53.41M	48.80M	200.72M	102.26M
Production and Sales of Raw Materials and Pharmaceutical Intermediates Growth	21.17%	9.44%	-75.69%	96.29%	-
Other	9.07M	11.69M	5.08M	9.85M	45.39M
Other Growth	-22.45%	130.12%	-48.43%	-78.30%	-
in Vitro Diagnostic Reagents	4.17M	-	-	-	-
offset of business segment	-25.71M	-	-	-	-
Total	541.45M	648.97M	602.28M	688.63M	614.68M
Total Growth	-16.57%	7.75%	-12.54%	12.03%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2020	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Jan 1, 2020	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
China	540.51M	645.31M	602.23M	684.49M	605.73M
China Growth	-16.24%	7.15%	-12.02%	13.00%	15.57%
Overseas	937.79K	3.66M	58.90K	4.13M	8.96M
Overseas Growth	-74.41%	6121.16%	-98.58%	-53.86%	-
Total	541.45M	648.97M	602.28M	688.63M	614.68M
Total Growth	-16.57%	7.75%	-12.54%	12.03%	17.28%

Source: S&P Global Market Intelligence.